198205-95-7

Usage

Uses

Used in Chemical Synthesis:
2'-Trifluoromethyl-biphenyl-4-carbaldehyde is used as a chemical intermediate for the synthesis of more complex molecules. Its unique molecular structure, with a trifluoromethyl group and a carbaldehyde group, allows it to participate in various chemical reactions, making it a valuable component in the creation of new compounds.
Used in Industrial Applications:
Although specific uses are not well-documented, 2'-Trifluoromethyl-biphenyl-4-carbaldehyde may be employed in industrial processes due to its chemical properties. Its potential applications could include the production of pharmaceuticals, agrochemicals, or other specialty chemicals that require its specific structural features.
Used in Research:
2'-Trifluoromethyl-biphenyl-4-carbaldehyde may be utilized in research settings to study its chemical properties, reactivity, and potential applications. Researchers may investigate its behavior in different reaction conditions or explore its use in the development of new materials or compounds.
Note: Due to the limited information available on 2'-Trifluoromethyl-biphenyl-4-carbaldehyde, the above uses are speculative and based on its chemical structure and potential applications in similar compounds. Further research and data are necessary to confirm its actual uses and safety profile.

Upstream product

• 444-29-1 2-iodo(trifluoromethyl)benzene 
• 1122-91-4 4-bromo-benzaldehyde 
• 1423-27-4 2-(trifluoromethyl)phenylboronic acid 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 87199-17-5 4-formylphenylboronic acid, 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 198205-79-7 2'-trifluoromethylbiphenyl-4-carboxylic acid 
• 198205-80-0 C₁₄H₁₁F₃O 
• 871250-39-4 (R,S)-2-cyclohexyl-1-(2'-trifluoromethylbiphenyl-4-yl)ethanol 

Relevant academic research and scientific papers

The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both in Vitro and in Vivo

The transient receptor potential melastatin 2 (TRPM2) channel is associated with ischemia/reperfusion injury, inflammation, cancer, and neurodegenerative diseases. However, the limit of specific inhibitors impedes the development of TRPM2-targeted therapeutic agents. To discover more potent and selective TRPM2 inhibitors, 59 N-(p-amylcinnamoyl) anthranilic acid (ACA) derivatives were synthesized and evaluated using calcium imaging and electrophysiology approaches. Systematic structure-activity relationship studies resulted in some potent compounds inhibiting the TRPM2 channel with sub-micromolar half-maximal inhibitory concentration values. Among them, the preferred compound A23 exhibited TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showed neuroprotective activity in vitro. Following pharmacokinetic studies, A23 was further evaluated in a transient middle cerebral artery occlusion model in vivo, which significantly reduced cerebral infarction. These data indicate that A23 might serve as a useful tool for TRPM2-related research as well as a lead compound for the development of therapeutic agents for ischemic injury.

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease

Monoamine oxidase-B (MAO-B) is a well-established therapeutic target for Parkinson’s disease (PD); however, previous clinical studies on currently available irreversible MAO-B inhibitors have yielded disappointing neuroprotective effects. Here, we tested the therapeutic potential of KDS2010, a recently synthesized potent, selective, and reversible MAO-B inhibitor in multiple animal models of PD. We designed and synthesized a series of α-aminoamide derivatives and found that derivative KDS2010 exhibited the highest potency, specificity, reversibility, and bioavailability (> 100%). In addition, KDS2010 demonstrated significant neuroprotective and anti-neuroinflammatory efficacy against nigrostriatal pathway destruction in the mouse MPTP model of parkinsonism. Treatment with KDS2010 also alleviated parkinsonian motor dysfunction in 6-hydroxydopamine-induced and A53T mutant α-synuclein overexpression rat models of PD. Moreover, KDS2010 showed virtually no toxicity or side effects in non-human primates. KDS2010 could be a next-generation therapeutic candidate for PD.

Discovery and structure-activity relationships of pyrrolone antimalarials

In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 ～ 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.

A general method for Suzuki-Miyaura coupling reactions using lithium triisopropyl borates

Conditions for the Suzuki-Miyaura coupling of lithium triisopropyl borates are reported, as well as a procedure for a one-pot lithiation, borylation, and subsequent Suzuki-Miyaura coupling of various heterocycles with aryl halides. These borate species are much more stable toward protodeboronation than the corresponding boronic acids and can conveniently be stored on benchtop at room temperature.

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

A convenient microwave assisted arylzinc generation-Negishi coupling protocol

Arylzinc reagents were readily prepared from aryl iodides using a Zn-Cu couple in a microwave environment. A sequential arylzinc formation-Negishi cross-coupling protocol suitable for parallel high-throughput synthesis has been developed.